Issuance of the 5th series convertible bonds with warrants by third-party allotment. Total principal 187,200,000 yen, conversion price 302.4 yen, interest rate 1.0% per annum, maturity date November 2, 2029. Allottee: Cantor Fitzgerald Europe. Proceeds to be used for drug discovery R&D and working capital. Estimated dilution approximately 19.17%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4572-20261019-01.pdf","jir_short_summary":"Issuance of the 5th series convertible bonds with warrants by third-party allotment. Total principal 187,200,000 yen, conversion price 302.4 yen, interest rate 1.0% per annum, maturity date November 2, 2029. Allottee: Cantor Fitzgerald Europe. Proceeds to be used for drug discovery R&D and working capital. Estimated dilution approximately 19.17%.","jir_summary":"### Overview of Fundraising\nCarna Biosciences, Inc. will issue the 5th series unsecured convertible bonds with warrants by third-party allotment under the program agreement dated September 28, 2026. The total principal amount of the bonds is 187,200,000 yen, the conversion price is 302.4 yen, the interest rate is 1.0% per annum, and the maturity date is November 2, 2029. The allottee is Cantor Fitzgerald Europe. The warrants will be exercised by issuance of shares without cash payment. Proceeds are planned to be allocated to drug discovery development expenses and working capital.\n\n### Dilution, Use of Proceeds and Outlook\nIf all conversions are executed, dilution is expected to be approximately 19.17% (ratio to total outstanding shares). The proceeds will be used for clinical development expenses, preclinical and overall R&D, and working capital. The selection of the allottee is supported by an independent fairness evaluation, and a certain level of liquidity is assumed.","jir_financial_highlights":"Total Principal Amount of Bonds: 187,200,000 yen (Unknown)\nInterest Rate of Convertible Bonds with Warrants: 1.0% per annum (Unknown)\nConversion Price: 302.4 yen (Unknown)\nNumber of Potential Shares: 687,830 shares (potential shares) (Unknown)\nMaturity Date: 2029-11-02 (Unknown)","jir_category":"","jir_hashtags":"#CarnaBiosciences, #CapitalPolicy, #ConvertibleBondsWithWarrants","jir_key_figures":"187,200,000 yen: Total principal amount of bonds\n302.4 yen: Conversion price\n687,830 shares: Number of potential shares\n2029-11-02: Maturity date\n19.17%: Estimated dilution","jir_meta_title":"Carna Biosciences, Inc. Announces 5th Series Third-Party Allotment of Convertible Bonds with Warrants | Securing Drug Discovery Funding","jir_meta_description":"Carna Biosciences, Inc. conducts a third-party allotment of the 5th series convertible bonds with warrants. Total principal 187 million yen, conversion price 302.4 yen, maturity 2029-11-02. Proceeds to fund drug discovery R&D and working capital; estimated dilution approximately 19.17%. Allottee: Cantor Fitzgerald Europe.","jir_og_title":"Carna Biosciences, Inc. Announces 5th Series Third-Party Allotment of Convertible Bonds with Warrants | Securing Drug Discovery Funding","jir_og_description":"Carna Biosciences, Inc. will issue the 5th series convertible bonds with warrants by third-party allotment. Conversion price 302.4 yen, interest rate 1.0%, maturity 2029-11-02. Proceeds to be used for drug discovery R&D and working capital; estimated dilution about 19.17%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-132670","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n